JP5832435B2 - ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体 - Google Patents

ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体 Download PDF

Info

Publication number
JP5832435B2
JP5832435B2 JP2012528860A JP2012528860A JP5832435B2 JP 5832435 B2 JP5832435 B2 JP 5832435B2 JP 2012528860 A JP2012528860 A JP 2012528860A JP 2012528860 A JP2012528860 A JP 2012528860A JP 5832435 B2 JP5832435 B2 JP 5832435B2
Authority
JP
Japan
Prior art keywords
par
antibody
human
antigen
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012528860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013504577A5 (cg-RX-API-DMAC10.html
JP2013504577A (ja
Inventor
リン マクドナルド，
リン マクドナルド，
アンドリュー ジェイ． マーフィー，
アンドリュー ジェイ． マーフィー，
ニコラス ジェイ． パパドプロス，
ニコラス ジェイ． パパドプロス，
マーク アール． モーラ，
マーク アール． モーラ，
ロバート アール． ソルズラー，
ロバート アール． ソルズラー，
マイケル エル． ラクア−フラリッシュ
マイケル エル． ラクア−フラリッシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2013504577A publication Critical patent/JP2013504577A/ja
Publication of JP2013504577A5 publication Critical patent/JP2013504577A5/ja
Application granted granted Critical
Publication of JP5832435B2 publication Critical patent/JP5832435B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012528860A 2009-09-09 2010-09-08 ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体 Expired - Fee Related JP5832435B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US24078309P 2009-09-09 2009-09-09
US61/240,783 2009-09-09
US24282109P 2009-09-16 2009-09-16
US61/242,821 2009-09-16
US31783910P 2010-03-26 2010-03-26
US61/317,839 2010-03-26
PCT/US2010/048034 WO2011031695A1 (en) 2009-09-09 2010-09-08 High affinity human antibodies to human protease-activated receptor-2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015177339A Division JP6055055B2 (ja) 2009-09-09 2015-09-09 ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体

Publications (3)

Publication Number Publication Date
JP2013504577A JP2013504577A (ja) 2013-02-07
JP2013504577A5 JP2013504577A5 (cg-RX-API-DMAC10.html) 2013-09-05
JP5832435B2 true JP5832435B2 (ja) 2015-12-16

Family

ID=43063654

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012528860A Expired - Fee Related JP5832435B2 (ja) 2009-09-09 2010-09-08 ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体
JP2015177339A Expired - Fee Related JP6055055B2 (ja) 2009-09-09 2015-09-09 ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015177339A Expired - Fee Related JP6055055B2 (ja) 2009-09-09 2015-09-09 ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体

Country Status (29)

Country Link
US (3) US8101724B2 (cg-RX-API-DMAC10.html)
EP (1) EP2475684B1 (cg-RX-API-DMAC10.html)
JP (2) JP5832435B2 (cg-RX-API-DMAC10.html)
KR (1) KR101766701B1 (cg-RX-API-DMAC10.html)
CN (1) CN102574923B (cg-RX-API-DMAC10.html)
AR (1) AR078346A1 (cg-RX-API-DMAC10.html)
AU (1) AU2010292342C1 (cg-RX-API-DMAC10.html)
BR (1) BR112012005338A2 (cg-RX-API-DMAC10.html)
CA (1) CA2773541A1 (cg-RX-API-DMAC10.html)
CY (1) CY1118714T1 (cg-RX-API-DMAC10.html)
DK (1) DK2475684T3 (cg-RX-API-DMAC10.html)
ES (1) ES2609780T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20170324T1 (cg-RX-API-DMAC10.html)
HU (1) HUE031725T2 (cg-RX-API-DMAC10.html)
IL (1) IL218501A (cg-RX-API-DMAC10.html)
JO (1) JO3246B1 (cg-RX-API-DMAC10.html)
LT (1) LT2475684T (cg-RX-API-DMAC10.html)
MX (1) MX2012002927A (cg-RX-API-DMAC10.html)
MY (1) MY159551A (cg-RX-API-DMAC10.html)
NZ (1) NZ599204A (cg-RX-API-DMAC10.html)
PL (1) PL2475684T3 (cg-RX-API-DMAC10.html)
PT (1) PT2475684T (cg-RX-API-DMAC10.html)
SG (1) SG178976A1 (cg-RX-API-DMAC10.html)
SI (1) SI2475684T1 (cg-RX-API-DMAC10.html)
SM (2) SMT201700102T1 (cg-RX-API-DMAC10.html)
TW (1) TWI492757B (cg-RX-API-DMAC10.html)
UY (1) UY32883A (cg-RX-API-DMAC10.html)
WO (1) WO2011031695A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201201730B (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
AP2014007588A0 (en) * 2011-09-22 2014-04-30 Amgen Inc CD27L antigen binding proteins
HK1223096A1 (zh) 2013-09-25 2017-07-21 Vertex Pharmaceuticals Incorporated 用作par-2信號通路抑制劑的咪唑並噠嗪
WO2015128846A1 (en) * 2014-02-28 2015-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region
WO2017023780A1 (en) 2015-07-31 2017-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates for targeting cd56-positive tumors
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
ES2984663T3 (es) 2015-11-13 2024-10-30 Oasis Pharmaceuticals Llc Moduladores del receptor 2 activados por proteasa
JP2019534044A (ja) 2016-11-08 2019-11-28 クイル ピュージェット サウンド バイオセラピューティクス コーポレーション 抗ｐｄ１および抗ｃｔｌａ４抗体
MA49886A (fr) 2017-03-16 2020-06-24 Medimmune Ltd Anticorps anti-par2 et leurs utilisations
US12077592B2 (en) * 2019-01-18 2024-09-03 Janssen Biotech, Inc. GPRC5D chimeric antigen receptors and cells expressing the same
AU2020250933A1 (en) 2019-04-05 2021-10-28 Centre Hospitalier Régional Et Universitaire De Brest Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
BR112021023897A2 (pt) 2019-05-30 2022-01-25 Shandong Boan Biotechnology Co Ltd Anticorpo ou receptor de antígeno quimérico que visa claudina18.2
WO2021084760A1 (ja) * 2019-11-01 2021-05-06 株式会社 資生堂 皮膚での活性型ｐａｒ－２を指標とした皮膚状態評価方法、ｐａｒ－２活性化促進剤又は抑制剤のスクリーニング方法及びｐａｒ－２活性化抑制剤
CN113248611B (zh) * 2020-02-13 2026-02-06 上海泰槿生物技术有限公司 抗bcma抗体、其药物组合物及应用
EP4126248A4 (en) 2020-03-31 2024-07-10 Fred Hutchinson Cancer Center HUMAN ANTI-CD33 ANTIBODIES AND THEIR USES
AU2021328375A1 (en) * 2020-08-18 2023-04-13 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof
JP2024535740A (ja) * 2021-09-02 2024-10-02 メモリアル スローン ケタリング キャンサー センター Ｃｄ３３を標的とする抗原認識受容体及びその使用
EP4396235A4 (en) * 2021-09-02 2025-07-02 Memorial Sloan Kettering Cancer Center ANTI-CD33 ANTIBODIES AND THEIR USES
CN114181311B (zh) * 2021-12-20 2023-06-20 华东师范大学 一种全人源抗DLL3 scFv及其在CART细胞治疗中的应用
GB202204159D0 (en) * 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
WO2024059336A1 (en) * 2022-09-18 2024-03-21 Memorial Sloan Kettering Cancer Center Inhibition of protease-activated receptor 2 (par2) pathway for treatment and prevention of lymphedema
CN118290572B (zh) * 2023-09-19 2026-04-07 军事科学院军事医学研究院军事兽医研究所 抗狂犬病病毒全人源抗体及其组合物与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297026B1 (en) 1993-07-26 2001-10-02 Cor Therapeutics Inc. Nucleic acids encoding the C140 receptor
EP1972194A1 (en) * 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US7888482B2 (en) * 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
WO2008086069A1 (en) * 2007-01-03 2008-07-17 The General Hospital Corporation Methods of treating itch
CL2008001887A1 (es) * 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
KR20090082619A (ko) 2008-01-28 2009-07-31 주식회사 알파크립텍 다프네틴을 함유하는 가려움증 또는 염증 개선용 화장료조성물
AR070911A1 (es) 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
WO2010017086A1 (en) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Effectors of par-2 activation and their use in the modulation of inflammation
CN102458356A (zh) 2009-06-18 2012-05-16 株式会社爱茉莉太平洋 含有栗子皮提取物的化妆料组合物
WO2010147440A2 (ko) 2009-06-18 2010-12-23 (주)아모레퍼시픽 밤껍질 추출물을 포함하는 건강 식품 또는 약학 조성물
FR2947452B1 (fr) 2009-07-01 2012-04-20 Fabre Pierre Dermo Cosmetique L-serine et/ou l-asparagine et/ou l-valine pour prevenir et/ou au traiter des reactions inflammatoires de la peau.
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري

Also Published As

Publication number Publication date
HK1166509A1 (en) 2012-11-02
US20110059095A1 (en) 2011-03-10
MX2012002927A (es) 2012-08-03
IL218501A0 (en) 2012-07-31
PL2475684T3 (pl) 2017-04-28
US8425907B2 (en) 2013-04-23
SG178976A1 (en) 2012-04-27
JP6055055B2 (ja) 2016-12-27
CN102574923A (zh) 2012-07-11
KR20120059611A (ko) 2012-06-08
TW201121565A (en) 2011-07-01
MY159551A (en) 2017-01-13
SMT201700102T1 (it) 2017-03-08
IL218501A (en) 2017-03-30
DK2475684T3 (en) 2017-03-06
SMT201700102B (it) 2017-03-08
ES2609780T3 (es) 2017-04-24
US20120093824A1 (en) 2012-04-19
TWI492757B (zh) 2015-07-21
LT2475684T (lt) 2017-01-25
AU2010292342B2 (en) 2015-04-30
HRP20170324T1 (hr) 2017-04-21
NZ599204A (en) 2014-05-30
CY1118714T1 (el) 2017-07-12
EP2475684B1 (en) 2016-11-30
PT2475684T (pt) 2017-02-10
WO2011031695A1 (en) 2011-03-17
CA2773541A1 (en) 2011-03-17
AU2010292342C1 (en) 2015-08-27
KR101766701B1 (ko) 2017-08-09
AU2010292342A1 (en) 2012-05-03
US9028819B2 (en) 2015-05-12
CN102574923B (zh) 2016-12-07
UY32883A (es) 2011-03-31
EP2475684A1 (en) 2012-07-18
SI2475684T1 (sl) 2017-03-31
ZA201201730B (en) 2012-11-28
US20140179903A1 (en) 2014-06-26
HUE031725T2 (en) 2017-08-28
JP2013504577A (ja) 2013-02-07
JP2015227381A (ja) 2015-12-17
JO3246B1 (ar) 2018-03-08
BR112012005338A2 (pt) 2016-11-22
AR078346A1 (es) 2011-11-02
US8101724B2 (en) 2012-01-24

Similar Documents

Publication Publication Date Title
JP6055055B2 (ja) ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体
JP7436603B2 (ja) レプチン受容体を活性化させる抗原結合タンパク質
CN104540852B (zh) 具有pH-依赖性结合特性的抗-PCSK9抗体
JP6367233B2 (ja) 抗ｐｄｇｆｒ−ベータ抗体及びそれらの使用
JP6654165B2 (ja) 抗ｔｉｅ２抗体およびその使用
TWI465249B (zh) 針對ｐｃｓｋ９之高親和性人類抗體
TW201701903A (zh) 抗人類ｇｄｆ８之抗體
JP7431750B2 (ja) カンナビノイド受容体１型（ｃｂ１）結合性タンパク質及びその使用
US20180208656A1 (en) Anti-Prokineticin Receptor (PROKR) Antibodies and Uses Thereof
HK1166509B (en) High affinity human antibodies to human protease-activated receptor-2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150909

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150917

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151013

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151027

R150 Certificate of patent or registration of utility model

Ref document number: 5832435

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees